COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028 -
-
COMMUNIQUÉ DE PRESSE
The Burkhalter Group exceeds expectations once again by posting excellent results for the 2025 financial year
Burkhalter Group exceeds expectations in 2025 with strong financial performance, proposing a dividend increase and targeting acquisitions. Focus on sustainability and positive outlook for 2026 -
COMMUNIQUÉ DE PRESSE
Le Groupe Burkhalter surpasse une nouvelle fois les attentes et clôture l’exercice 2025 sur d’excellents résultats
Le Groupe Burkhalter dépasse les attentes avec d'excellents résultats financiers en 2025 et propose un dividende de CHF 5.20 par action. Acquisitions et engagement pour l'environnement renforcés -
-
-
COMMUNIQUÉ DE PRESSE
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)
BioVersys AG and partners publish pre-clinical development data of AlpE in Nature Communications, showcasing unique Mechanism of Action targeting drug-resistance in tuberculosis -
-
